Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

Stull, Donald E.; Griffiths, Cem; Gilloteau, I.; Zhao, Yang; Guana, Adriana; Finlay, Andrew Y.; Sherif, Bintu; Houghton, Katherine; Puig, L.

doi:10.1111/bjd.16366

Cited by 11 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the two main disease symptoms, PASI and itch, as the mediators, the mediation analysis showed that both early improvement in itch and PASI scores played a role in improving patient's quality-of-life at Weeks 4 and 12, with improvement in itch playing a more dominant role than PASI score. Similar results were shown previously in patients with moderate-to-severe psoriasis (6, 10, 11) using a single mediator (6) or more complex models with several factors including PASI, itch, pain, scaling (11). There were limitations in this mediation analysis.…”

Section: Discussionsupporting

confidence: 81%

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis

Yosipovitch

Dong²,

Burge

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 81%

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis

Yosipovitch

Dong²,

Burge

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

“…There are two arguments underpinning the feasibility of this alternative scoring formula. Firstly, in a recent study, Stull et al . performed structural equation modelling and showed that in patients with psoriasis, the symptoms of psoriasis first affect the symptoms and feelings subscale, which then has an impact on the remaining five subscales.…”

Section: Methodsmentioning

confidence: 99%

Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Associations between improvements in PASI score and either itching or HRQoL exist but do not reach levels indicating very high correlation (ie, a correlation coefficient [0.9). 34 Itching may be an even stronger determinant of patient-perceived quality of life than PASI score is. 35 Therefore, the attributes evaluated here can be considered in the same conjoint analysis.…”

Section: Survey Approachmentioning

confidence: 99%

Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States

Feldman

Régnier

Chirilov

et al. 2019

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

and Chicago, IllinoisBackground: Psoriasis Area and Severity Index (PASI) response rates have been the benchmark for evaluating treatment efficacy in trials involving moderate-to-severe psoriasis.Objective: To understand how dermatologists assess biologics and which trade-off rules they apply when planning psoriasis treatment.Methods: Two online surveys of 130 and 129 US dermatologists (surveys 1 and 2, respectively) were conducted with use of direct and indirect elicitation via discrete choice experiment. Respondents were asked to choose hypothetical biologics on the basis of 6 attributes (a $75% reduction from baseline in PASI score or a $90% reduction from baseline in PASI score, infection risk, dosing frequency, and 3 patientreported outcomes [PROs] [relief of depression, relief of itching, and impact on usual activities]).Results: Most dermatologists (74% in survey 1 and 76% in survey 2) reported using both PASI and PROs when selecting a biologic. PASI response rate was the most important attribute (35%-38% of overall decision weight), whereas combined PRO attributes had similar importance (36% of decision weight). Infection risk and dosing frequency influenced the decision to a lesser extent.Limitations: Potential bias in considering 3 PROs versus 1 PASI rate and 1 safety attribute.Conclusion: PASI is most important for dermatologists selecting biologics, but PROs are also considered, especially when PASI response rate is similar between treatments. PRO data should be collected in trials involving moderate-to-severe psoriasis. ( J Am Acad Dermatol 2019;80:1650-7.)

show abstract

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

Abstract: The results underscore the important role of both PASI response and reduction in symptoms on improvements in health-related quality of life and work and daily activity in favour of secukinumab vs. ustekinumab.

Cited by 11 publications

References 26 publications

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis

Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis

Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States

Contact Info

Product

Resources

About